{Reference Type}: Journal Article
{Title}: Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.
{Author}: Skeate JG;Pomeroy EJ;Slipek NJ;Jones BJ;Wick BJ;Chang JW;Lahr WS;Stelljes EM;Patrinostro X;Barnes B;Zarecki T;Krueger JB;Bridge JE;Robbins GM;McCormick MD;Leerar JR;Wenzel KT;Hornberger KM;Walker K;Smedley D;Largaespada DA;Otto N;Webber BR;Moriarity BS;
{Journal}: Mol Ther
{Volume}: 32
{Issue}: 6
{Year}: 2024 Jun 5
{Factor}: 12.91
{DOI}: 10.1016/j.ymthe.2024.04.024
{Abstract}: Cellular therapies for the treatment of human diseases, such as chimeric antigen receptor (CAR) T and natural killer (NK) cells have shown remarkable clinical efficacy in treating hematological malignancies; however, current methods mainly utilize viral vectors that are limited by their cargo size capacities, high cost, and long timelines for production of clinical reagent. Delivery of genetic cargo via DNA transposon engineering is a more timely and cost-effective approach, yet has been held back by less efficient integration rates. Here, we report the development of a novel hyperactive TcBuster (TcB-M) transposase engineered through structure-guided and in vitro evolution approaches that achieves high-efficiency integration of large, multicistronic CAR-expression cassettes in primary human cells. Our proof-of-principle TcB-M engineering of CAR-NK and CAR-T cells shows low integrated vector copy number, a safe insertion site profile, robust in vitro function, and improves survival in a Burkitt lymphoma xenograft model in vivo. Overall, TcB-M is a versatile, safe, efficient and open-source option for the rapid manufacture and preclinical testing of primary human immune cell therapies through delivery of multicistronic large cargo via transposition.